IL6 and esophageal squamous cell carcinoma: We discovered that the baseline plasma IL-6 levels, number of distant metastatic organs at the start of PD-1 inhibitor treatment, ECOG score, and number of treatment lines were associated with PFS in advanced ESCC patients.